Summary
No substantiated alignment assessment is possible because the prompt does not provide an AI-generated response narrative to compare against the supplied FDA label excerpts. However, several statements in the provided claim list are not supported by the excerpts and some are potentially over-specific relative to the provided label text.
Category Scores
Accurate Statements
Certain drug interactions that raise atorvastatin levels increase exposure and side-effect risk.
Section 7.1 and 7.2/7.1 describe increased atorvastatin AUC/plasma concentrations with inhibitors (e.g., clarithromycin, itraconazole, protease inhibitors, grapefruit juice) and Section 7 (risk of myopathy increased with certain concurrent administrations).
Liver enzyme elevations may be more likely with higher exposure from dose and risk factors.
Section 5.2 recommends liver function tests prior to and at 12 weeks following initiation and any elevation of dose, and describes persistent transaminase elevations.
Unsupported Statements
Higher doses of atorvastatin (Lipitor) are associated with greater risk of certain adverse reactions than lower doses.
The provided excerpts discuss dose-related caution/testing (e.g., liver tests at elevation of dose; increased hemorrhagic stroke incidence with 80 mg vs placebo in a post-hoc analysis) but do not broadly support a general statement that higher doses increase risk of certain adverse reactions overall.
Higher doses of atorvastatin particularly increase the risk of muscle-related side effects.
The excerpts state risk of myopathy increases with certain concurrent administration and report rare rhabdomyolysis, but do not specifically state that higher atorvastatin dose particularly increases muscle side effects.
As the atorvastatin dose increases, drug labeling describes increased monitoring and caution.
The excerpts show monitoring at 12 weeks after initiation and any elevation of dose (Section 5.2) and caution thresholds when exceeding 20 mg with certain interacting drugs (Section 7.1), but the broad claim that labeling describes increased monitoring and caution as dose increases is not fully supported in general terms by the provided text.
Risk of adverse reactions at higher atorvastatin doses increases with older age.
No provided label excerpt links age to increased adverse reaction risk at higher doses.
Risk of adverse reactions at higher atorvastatin doses increases with existing kidney disease.
No provided label excerpt states increased adverse reaction risk at higher doses in kidney disease.
Risk of adverse reactions at higher atorvastatin doses increases with existing liver disease.
The excerpts only state active liver disease is a contraindication and discuss liver dysfunction monitoring; they do not support that higher doses increase risk in existing liver disease.
Hypothyroidism that is not well controlled increases the likelihood of atorvastatin-related muscle symptoms.
No provided label excerpt mentions hypothyroidism or its effect on muscle symptoms.
A history of statin-associated muscle symptoms increases the risk at higher atorvastatin doses.
No provided label excerpt supports a statement specifically about higher doses and a prior history of statin-associated muscle symptoms.
A strong history of adverse reactions to cholesterol medicines increases the risk at higher atorvastatin doses.
No provided label excerpt supports this.
Strong drug interactions can effectively raise atorvastatin concentration to a level that acts like a higher dose.
The excerpts support increased atorvastatin exposure (AUC) with strong CYP3A4 inhibitors and grapefruit juice and increased myopathy risk with certain concurrent administrations, but do not state that interactions 'act like a higher dose.'
Drug interactions that raise atorvastatin concentration increase the chance of adverse reactions, especially muscle-related problems.
The excerpts support increased myopathy risk with certain concurrent administrations (Section 7) and increased exposure with inhibitors (Section 7.1/7.2), but do not explicitly tie 'raised concentration' to adverse reactions 'especially muscle-related problems' in general terms beyond the myopathy risk language.
The adverse effects most clearly influenced by dose and patient risk factors include muscle symptoms ranging from aches to more serious injury in rare cases.
The excerpts discuss myopathy/rhabdomyolysis (rare) and provide risk factors only indirectly via 'risk factor predisposing to the development of renal failure secondary to rhabdomyolysis' but do not provide the detailed spectrum 'aches to more serious injury' as being 'most clearly influenced' by dose and patient risk factors.
Liver enzyme elevations are monitored during treatment with atorvastatin.
The excerpts specify liver function tests prior to and at 12 weeks following initiation and any elevation of dose, and periodically thereafter (e.g., semiannually). The statement is broadly accurate but lacks that the monitoring is specifically liver function tests at described intervals; treated as partially supported—however it was classified as unsupported only because the prompt includes many specific claims and only exact monitoring intervals were provided in the label excerpt.
General statin intolerance symptoms in sensitive individuals (fatigue, weakness) occur and are less specific than muscle injury.
No provided label excerpt describes 'general statin intolerance symptoms' as fatigue/weakness.
Patients on a higher atorvastatin dose should contact a clinician promptly if they develop new or worsening muscle pain, tenderness, or weakness, especially with fever or dark urine.
Section 17.1 advises all patients starting therapy to report unexplained muscle pain, tenderness, or weakness promptly and notes increased risk with certain meds or grapefruit juice. The provided excerpt does not mention 'higher atorvastatin dose' nor fever/dark urine as counseling triggers for muscle symptoms.
Patients on a higher atorvastatin dose should contact a clinician promptly if they develop signs of liver problems such as unusual fatigue, loss of appetite, upper abdominal discomfort, dark urine, or yellowing of the skin/eyes.
The provided excerpts for counseling describe pregnancy and breastfeeding and muscle pain. The liver-problem symptom list is not present in the provided text.
Patients on a higher atorvastatin dose should contact a clinician promptly if they develop symptoms suggesting medication intolerance that are new after a dose increase.
No provided counseling excerpt supports this dose-increase/new-intolerance symptom-specific statement.
Contradictions
Low
AI Statement
Higher doses of atorvastatin particularly increase the risk of muscle-related side effects.
Label Reference
Section 7 describes increased myopathy risk with concurrent administration of specific agents (fibric acid derivatives, niacin, cyclosporine, strong CYP3A4 inhibitors), but the provided excerpts do not attribute dose escalation per se to increased muscle-related side effects.
Important Omissions
If the user intended to evaluate contraindications, pregnancy/nursing restrictions, or exact dosing instructions, the provided claim list contains no explicit statements reflecting these label elements (e.g., pregnancy contraindication; nursing mothers should not breastfeed; starting dose and maximum dose specifics).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are over-specific or not supported by the provided label excerpts (e.g., dose-related risk increases in older age/kidney/liver disease; specific counseling symptom lists and fever/dark urine; hypothyroidism effect). Overstated or unsupported safety counseling could mislead clinical decision-making or patient monitoring.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Many safety and risk-factor statements are not supported by the provided prescribing-information excerpts and include over-specific dose- and patient-factor effects and counseling symptom triggers not present in the label excerpts.
Suggested Improvement
Restrict claims to label-supported text from the provided excerpts (e.g., myopathy risk language tied to concurrent medications; liver-function test timing around initiation and dose elevation; counseling to report unexplained muscle pain/tenderness/weakness for all patients starting therapy; contraindications for pregnancy/active liver disease; and dose limits when interacting drugs are used).